Confirmation of large BRCA2 reversion deletions leading to reconstituted in-frame transcripts detected via circulating tumor DNA.
作者信息
Collier K A, Stover D G
机构信息
Division of Medical Oncology, Ohio State University Comprehensive Cancer Center, Columbus; Pelotonia Institute for Immuno-Oncology, Ohio State University Comprehensive Cancer, Columbus.
Division of Medical Oncology, Ohio State University Comprehensive Cancer Center, Columbus; Pelotonia Institute for Immuno-Oncology, Ohio State University Comprehensive Cancer, Columbus; Department of Biomedical Informatics, Ohio State University, Columbus, USA.
出版信息
Ann Oncol. 2024 Oct;35(10):917-919. doi: 10.1016/j.annonc.2024.07.720. Epub 2024 Jul 22.
Abstract
摘要
相似文献
1
Confirmation of large BRCA2 reversion deletions leading to reconstituted in-frame transcripts detected via circulating tumor DNA.通过循环肿瘤DNA检测到导致重新构建的框内转录本的大型BRCA2回复缺失的确认。
Ann Oncol. 2024 Oct;35(10):917-919. doi: 10.1016/j.annonc.2024.07.720. Epub 2024 Jul 22.
2
Diverse and Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer.耐药性乳腺癌或卵巢癌循环游离 DNA 中的多种和回复突变。
Clin Cancer Res. 2017 Nov 1;23(21):6708-6720. doi: 10.1158/1078-0432.CCR-17-0544. Epub 2017 Aug 1.
3
Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Circulating Tumor DNA in Breast Cancer.下一代测序在乳腺癌肿瘤组织与循环肿瘤 DNA 中基因组改变的一致性。
Mol Cancer Ther. 2017 Jul;16(7):1412-1420. doi: 10.1158/1535-7163.MCT-17-0061. Epub 2017 Apr 26.
4
Identification of Somatically Acquired Mutations by cfDNA Analysis in Patients with Metastatic Breast Cancer.通过 cfDNA 分析鉴定转移性乳腺癌患者的体细胞获得性突变。
Clin Cancer Res. 2020 Sep 15;26(18):4852-4862. doi: 10.1158/1078-0432.CCR-20-0638. Epub 2020 Jun 22.
5
Assessment of genome mutation analysis for tumor-informed detection of circulating tumor DNA in patients with breast cancer.用于乳腺癌患者循环肿瘤DNA肿瘤信息检测的基因组突变分析评估
Clin Chim Acta. 2024 Jul 15;561:119818. doi: 10.1016/j.cca.2024.119818. Epub 2024 Jun 13.
6
BRCA2 Reversion Mutation Associated With Acquired Resistance to Olaparib in Estrogen Receptor-positive Breast Cancer Detected by Genomic Profiling of Tissue and Liquid Biopsy.通过组织和液体活检的基因组分析检测到的与雌激素受体阳性乳腺癌中奥拉帕尼获得性耐药相关的BRCA2回复突变
Clin Breast Cancer. 2018 Apr;18(2):184-188. doi: 10.1016/j.clbc.2017.12.010. Epub 2017 Dec 21.
7
Identification of a new complex deleterious mutation in exon 18 of the BRCA2 gene in a hereditary male/female breast cancer family.鉴定一个遗传性男性/女性乳腺癌家族中 BRCA2 基因第 18 外显子的新的复杂有害突变。
Breast Cancer Res Treat. 2010 Sep;123(2):587-90. doi: 10.1007/s10549-010-0830-2. Epub 2010 Mar 16.
8
The BRCA2 variant 8204G>A is a splicing mutation and results in an in frame deletion of the gene.BRCA2基因的8204G>A变异是一种剪接突变，会导致该基因发生框内缺失。
J Med Genet. 2003 Mar;40(3):e23. doi: 10.1136/jmg.40.3.e23.
9
, , and Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical Aggression.、 和 缺陷以不同方式塑造前列腺肿瘤驱动基因组学和临床侵袭性。
Clin Cancer Res. 2021 Mar 15;27(6):1650-1662. doi: 10.1158/1078-0432.CCR-20-3708. Epub 2021 Jan 7.
10
Analysis of large deletions in BRCA1, BRCA2 and PALB2 genes in Finnish breast and ovarian cancer families.芬兰乳腺癌和卵巢癌家族中BRCA1、BRCA2和PALB2基因大片段缺失的分析。
BMC Cancer. 2008 May 26;8:146. doi: 10.1186/1471-2407-8-146.
本文引用的文献
1
Longitudinal profiling identifies co-occurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer.纵向分析鉴定出 PARP 抑制剂耐药的晚期乳腺癌中同时存在 BRCA1/2 回复突变、TP53BP1、RIF1 和 PAXIP1 突变。
Ann Oncol. 2024 Apr;35(4):364-380. doi: 10.1016/j.annonc.2024.01.003. Epub 2024 Jan 19.
2
Association of 17q22 Amplicon Via Cell-Free DNA With Platinum Chemotherapy Response in Metastatic Triple-Negative Breast Cancer.游离 DNA 中 17q22 扩增与转移性三阴性乳腺癌铂类化疗反应的关联。
JCO Precis Oncol. 2021 Nov 24;5. doi: 10.1200/PO.21.00104. eCollection 2021.
3
Modeling clonal structure over narrow time frames via circulating tumor DNA in metastatic breast cancer.通过转移性乳腺癌的循环肿瘤 DNA 对狭窄时间范围内的克隆结构进行建模。
Genome Med. 2021 May 20;13(1):89. doi: 10.1186/s13073-021-00895-x.
4
PARP inhibitors: Synthetic lethality in the clinic.聚（ADP-核糖）聚合酶抑制剂：临床中的合成致死性
Science. 2017 Mar 17;355(6330):1152-1158. doi: 10.1126/science.aam7344. Epub 2017 Mar 16.
5
Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors?分子通路：BRCA 突变型肿瘤如何对 PARP 抑制剂产生耐药性？
Clin Cancer Res. 2014 Feb 1;20(3):540-7. doi: 10.1158/1078-0432.CCR-13-0225. Epub 2013 Nov 22.
Zotero 插件